PerkinElmer adjusts Q1 2020 revenue down

LabPulse.com staff writers
Mar 9, 2020
2019 08 27 23 28 6391 Graph Bar Down 400

PerkinElmer announced that it anticipates its first quarter 2020 revenue to be lower than previously expected.

The adjustment comes after decreased demand in China due to the extension of the Lunar New Year holiday and commercial disruptions due to COVID-19, the company said.

"While we have yet to see significant disruption outside of China, we are keenly monitoring the recent virus-related developments across the globe, as increased transmission rates globally could further impact our current and future financial performance," Prahlad Singh, president and CEO, said in a statement.

Latest in Diagnostic Technologies
Breast Mammo Social
AI model could prevent unnecessary treatment for breast cancer patients, says study
November 30, 2023
Crispr Cas9 Gene Editing Social
KSQ Therapeutics receives FDA clearance for trial of CRISPR-Cas9 engineered tumor therapy
November 29, 2023
Dna Sequence Social
Nanopore sequencing slashes tumor analysis times and costs
November 28, 2023
Heart Pulmonary Trunk Social
AI-powered blood test supports risk stratification of heart disease patients
November 27, 2023
Related Stories
2022 02 02 22 58 0725 Graph Market Down 400
Infectious
PerkinElmer's diagnostics revenue, income dip in Q4
2020 06 17 20 35 0417 Covid 19 Antibody 400
Emergency Use Authorization
PerkinElmer debuts dried blood spot-based COVID-19 serology test
2019 12 03 21 13 6201 Home Magnifying Glass 400
Molecular Diagnostics
PerkinElmer says it's not target of federal probe
2020 05 07 21 48 0194 Men Working Business 400
Financial Results
PerkinElmer Q1 revenues edge up, profit edges down
More in Diagnostic Technologies
AI model could prevent unnecessary treatment for breast cancer patients, says study
Breast cancer patients could be spared unnecessary chemotherapy with the use of a new artificial intelligence (AI) tool that helps predict survival risk, say researchers.
November 30, 2023
Breast Mammo Social
KSQ Therapeutics receives FDA clearance for trial of CRISPR-Cas9 engineered tumor therapy
Biotech firm KSQ Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a phase I and II trial of KSQ-001EX, KSQ’s CRISPR-Cas9 engineered tumor-infiltrating lymphocyte program.
November 29, 2023
Crispr Cas9 Gene Editing Social
Nanopore sequencing slashes tumor analysis times and costs
Nanopore sequencing makes the analysis of copy number variations (CNVs) faster, cheaper, and simpler, according to a preprint paper from researchers at Dartmouth-Hitchcock Medical Center.
November 28, 2023
Dna Sequence Social
AI-powered blood test supports risk stratification of heart disease patients
A blood test powered by artificial intelligence (AI) has shown promise in the assessment of patients with total blockage of a heart artery.
November 27, 2023
Heart Pulmonary Trunk Social
Bit.bio unveils cell therapy candidate for liver conditions
Synthetic biology company bit.bio has unveiled a lead cell therapy candidate as a treatment for life-threatening liver conditions, and it has set out its broader cell therapy pipeline.
November 22, 2023
Liver Anatomy Social
U.K. regulators approve "world-first" sickle-cell gene therapy
U.K. medical regulators have approved a “world-first” gene therapy that aims to cure two blood disorders: sickle cell disease and transfusion-dependent β-thalassemia. They are the first regulatory body to approve the treatment.
November 20, 2023
Sickle Cell Anemia2 Social
AI concurs with humans in heart failure test, suggesting scalable approach to clinical trials
Artificial intelligence (AI) may make clinical trials more efficient by accurately identifying events at scale, a retrospective analysis has found.
November 21, 2023
Computer Heart Social
Verici DX, Thermo Fisher Scientific sign licensing agreement on pre-transplant prognostic test
Transplant diagnostic firm Verici DX and Thermo Fisher Scientific have signed an exclusive global licensing and commercialization agreement to develop a pre-transplant prognostic test for early kidney rejection risk assessment.
November 17, 2023
Kidneys Closeup Social
Zymo Research, Ad Astra Diagnostics receive FDA 510(k) clearances
Molecular diagnostics firm Zymo Research and rapid diagnostics developer Ad Astra Diagnostics have both received 510(k) clearances from the U.S. Food and Drug Administration.
November 16, 2023
Fda Button Social
Networks of wearable sensors capture body sounds to improve patient monitoring
Researchers have developed soft, miniaturized wearable devices to continuously capture the sounds of breathing and other bodily functions.
November 16, 2023
A health care worker places the wearable devices across a patient's chest to capture sounds throughout the lungs that are associated with breathing. Photo courtesy of Northwestern University.
AnchorDx, DiaCarta to collaborate on cancer diagnostics
Biotech company AnchorDx has entered into a long-term partnership with molecular diagnostics firm DiaCarta to develop and commercialize cancer diagnostic products for the global market.
November 14, 2023
Hands Shaking Deal Social
AI model shows promise detecting COVID-19 in low-resource settings
An artificial intelligence (AI) model shows promise for diagnosing COVID-19 in low-resource settings with severe shortages of medical experts, including in many African regions, according to a study published November 11 in Scientific Reports.
November 14, 2023
Artificial Intelligence Ai Hand Social
Page 1 of 303
Next Page